PMID- 20870686
OWN - NLM
STAT- MEDLINE
DCOM- 20110107
LR  - 20181201
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
VI  - 17
IP  - 4
DP  - 2010 Dec
TI  - Hormonal contraception and risk of endometrial cancer: a systematic review.
PG  - R263-71
LID - 10.1677/ERC-10-0076 [doi]
AB  - More than 15 case-control studies and at least four large cohort studies 
      demonstrated a decrease in the risk of endometrial cancer of about 50% for ever 
      use of combined oral contraceptives (COCs). In most of these studies, this 
      protective effect persisted for more than 10-15-20 years after cessation of the 
      COC. An increasing protective effect with longer duration of COC use has been 
      found in most studies. The beneficial effect was independent of the composition 
      of COC, i.e. dosage and type of progestogen, combined with ethinyl estradiol 
      30-50  mug/day. COCs with higher progestogen potency seem to be somewhat more 
      effective. Nonhormonal uterine devices have also been found to be strongly 
      protective; however, data on oral or injectable progestogen-only preparations 
      (POPs) including the levonorgestrel-releasing intrauterine system (LNG-IUS) are 
      still rare, but also suggest similar protective action. COCs, POPs, as well as 
      LNG-IUS can effectively reduce endometrial hyperplasia but should only be used in 
      exceptional cases in patients with or after endometrial cancer. In contrast to 
      nonhormonal IUS, systemic side effects cannot be excluded with LNG-IUS, but they 
      are certainly rare, as the main effect has decreased the endometrial estrogen 
      response because of the high endometrial tissue levels of LNG.
FAU - Mueck, Alfred O
AU  - Mueck AO
AD  - Department of Endocrinology and Menopause, Centre for Women's Health BW, 
      University Women's Hospital, Calwer Strasse 7, D-72076 Tuebingen, Germany. 
      alfred.mueck@med.uni-tuebingen.de
FAU - Seeger, Harald
AU  - Seeger H
FAU - Rabe, Thomas
AU  - Rabe T
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20100923
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
RN  - 0 (Contraceptives, Oral, Hormonal)
SB  - IM
MH  - Contraceptives, Oral, Hormonal/*administration & dosage
MH  - Endometrial Neoplasms/*epidemiology/etiology
MH  - Female
MH  - Humans
MH  - Risk Factors
EDAT- 2010/09/28 06:00
MHDA- 2011/01/08 06:00
CRDT- 2010/09/28 06:00
PHST- 2010/09/28 06:00 [entrez]
PHST- 2010/09/28 06:00 [pubmed]
PHST- 2011/01/08 06:00 [medline]
AID - 17/4/R263 [pii]
AID - 10.1677/ERC-10-0076 [doi]
PST - epublish
SO  - Endocr Relat Cancer. 2010 Sep 23;17(4):R263-71. doi: 10.1677/ERC-10-0076. Print 
      2010 Dec.